Please upgrade your browser.
Contrary to claims made by some Democratic detractors, detailed GOP proposals, and a bipartisan bill with several GOP cosponsors, do exist.
Wideout crowned team champion in Xbox tourney as Nittany Lions look to call attention to Global Rare Disease Day. The action included a stunning upset in the first round.
A phase II clinical trial of ixabepilone , an epothilone B analog, in patients with metastatic renal cell carcinoma
This phase II study was conducted to assess the efficacy and safety of ixabepilone in patients with metastatic renal cell carcinoma. Ixabepilone can cause tumor regression in some patients with metastatic renal cell carcinoma and could be considered in combination regimens with other therapies.
Psoriasis is thought to be angiogenesis dependent. Clear cell renal cell carcinoma is a hypervascularized solid tumor associated with loss of function of the von Hippel_Lindau (VHL) tumor suppressor.
The field of RCC biology continues to rapidly change. As new targeted strategies to control this cancer evolve, so do both the clinical strategies, and the strategies to measure response and predict outcome.
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: Comparison with the Memorial Sloan-Kettering prognostic factors model
The treatment paradigm in advanced renal cell carcinoma (RCC) has changed in the recent years. Sunitinib has been established as a new standard for first-line therapy. We studied the prognostic significance of baseline characteristics and we compared the risk stratification with the established Memorial Sloan Kettering Cancer Center (MSKCC) model. Studies on risk stratification of patients with advanced RCC treated with targeted therapies are warranted. Our results suggest that a simpler than the MSKCC model can be developed.
Data detailed in 'Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients' have been presented. According to recent research from Yamagata, Japan, "Incidence rate of renal cell carcinoma (RCC) differs among countries. The rates of Asian countries are lower than those of countries in North America or Europe but are exceptionally high in Japanese males."
|Powered by NeonCRM|